about
Fcγ-receptor IIIA polymorphism p.158F has no negative predictive impact on rituximab therapy with and without sequential chemotherapy in CD20-positive posttransplant lymphoproliferative disorder.Response to Rituximab Induction Is a Predictive Marker in B-Cell Post-Transplant Lymphoproliferative Disorder and Allows Successful Stratification Into Rituximab or R-CHOP Consolidation in an International, Prospective, Multicenter Phase II Trial.Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial.Plasmablastic posttransplant lymphoma: cytogenetic aberrations and lack of Epstein-Barr virus association linked with poor outcome in the prospective German Posttransplant Lymphoproliferative Disorder Registry.Early and late posttransplant lymphoproliferative disorder after lung transplantation--34 cases from the European PTLD Network.End-of-treatment positron emission tomography after uniform first-line therapy of B cell posttransplant lymphoproliferative disorder identifies patients at low risk of relapse in the prospective German PTLD registry.IL-6 and IL-10 in post-transplant lymphoproliferative disorders development and maintenance: a longitudinal study of cytokine plasma levels and T-cell subsets in 38 patients undergoing treatment.Haemorrhage due to proteolysis of FXIII and hyperfibrinolysis under vemurafenib treatment of metastatic melanoma.Immunosuppression is associated with clinical features and relapse risk of B cell posttransplant lymphoproliferative disorder: A retrospective analysis based on the prospective, international, multicenter PTLD-1 trialsEffect of dexamethasone on pulmonary and renal angiotensin-converting enzyme concentration in fetal sheep during late gestationBaseline differential blood count and prognosis in CD20-positive post-transplant lymphoproliferative disorder in the prospective PTLD-1 trialSerum-free light chains adjusted for renal function are a potential biomarker for post-transplant lymphoproliferative disorders
P50
Q37704588-88DBA6D4-9B31-4D51-92EC-B82738AAB6EBQ38383351-B2509169-0666-4DC1-AE8A-1F4961B1F763Q42628866-EFD91468-757C-4CD0-A5A3-3A4629779E87Q44172624-E611ECDB-F1E9-4C97-AF43-604339902DFFQ45132382-CAD46728-0CA0-4933-B2E9-55DCE2FE44E7Q49492748-B218F85A-3D82-479C-ACA1-858FD7A94FCBQ52894728-B1B0B489-D6CE-4C9D-89E6-6AF3BF98B15CQ53755915-F2611A6A-7BEC-44FB-8F3E-0C26FDAFC7DBQ56966827-2897178F-8DC2-4612-B950-EC871EBF0624Q79317909-F4F6DFF2-C7BA-436A-AFC0-BDB911A624A5Q86591654-B56EFFB9-2EB5-4201-8A02-C256165AA444Q91214481-5C091B02-0ED2-45A4-B27F-8752417977BA
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Heiner Zimmermann
@en
Heiner Zimmermann
@nl
type
label
Heiner Zimmermann
@en
Heiner Zimmermann
@nl
prefLabel
Heiner Zimmermann
@en
Heiner Zimmermann
@nl
P31
P496
0000-0002-4242-275X